52 results
8-K
EX-99.1
INBX
Inhibrx Biosciences, Inc.
9 May 24
Inhibrx Reports First Quarter 2024 Financial Results
4:08pm
finance and accounting team and its commercial strategy and medical affairs team;
◦an increase in professional service expenses related to accounting
DEFM14A
INBX
Inhibrx Biosciences, Inc.
26 Apr 24
Proxy related to merger
4:06pm
of Company management meet and consider, on an ongoing basis, the Company’s long-term strategy and the range of strategic opportunities available … associated with the Company’s stand-alone strategy and the potential impact of such risks and uncertainties on the trading price of the Company common
8-K
EX-99.1
INBX
Inhibrx Biosciences, Inc.
28 Feb 24
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
9:12am
in personnel-related costs, primarily related to an increase in headcount as the Company continues to build its commercial strategy and medical affairs
DEFA14A
adgvo2o norv
23 Jan 24
Additional proxy soliciting materials
6:38am
8-K
EX-2.1
ntfha8z
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
EX-2.2
lj22amh8bayqvhfe
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
EX-99.1
1d4 5j638f3830e
9 Nov 23
Inhibrx Reports Third Quarter 2023 Financial Results
4:03pm
8-K
EX-99.2
a8hiqeftm tbaib
7 Aug 23
Inhibrx Reports Second Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
vakgbw0mep q9i
7 Aug 23
Inhibrx Reports Second Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
n2q8567 g5173g3142
8 May 23
Inhibrx Reports First Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
0ia4q5203flh5gv
16 Nov 22
Regulation FD Disclosure
9:01am
8-K
EX-99.1
y3lpa8m
7 Nov 22
Inhibrx Reports Third Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
yu58zesj
4 Oct 22
Entry into a Material Definitive Agreement
8:02am